CN-121978333-A - Biomarker for diagnosing bladder cancer and application thereof

Abstract

The invention provides a biomarker for diagnosing bladder cancer and application thereof, and the biomarker is used for finding that ZDHC 20 is continuously increased in the process of converting bladder epithelial cells into malignant cells and is remarkably and highly expressed in human bladder cancer tissues through analyzing single cell transcriptome data of normal bladder epithelial cells and bladder cancer cells. Functional studies show that the over-expression of ZDHC 20 can obviously activate the cancer promotion signal paths such as PI3K/AKT, wnt/beta-catenin, cell cycle and the like, so that normal bladder epithelial cells can obtain the malignant growth capacity independent of adherence. The above results indicate that zdhc 20 is an important molecule driving malignant transformation of bladder epithelial cells. The invention discloses a key role of ZDHC 20 in bladder cancer occurrence, which indicates that ZDHC 20 can be used as a bladder cancer diagnosis and treatment target.

Inventors

• LI TENGDA

Assignees

• 温州医科大学

Dates

Publication Date

20260505

Application Date

20260408

Claims (5)

1. 1. The application of a biomarker detection reagent in preparing a reagent for detecting and diagnosing bladder cancer is characterized in that the biomarker is enzyme ZDHC 20 for catalyzing protein palmitoylation modification.
2. 2. The use according to claim 1, wherein the enzyme zdhc 20 is a marker for early diagnosis of bladder cancer.
3. Application of ZDHHC20 as target in preparing medicine for treating bladder cancer.
4. 4. The use according to claim 3, wherein the medicament for treating bladder cancer is a zdhc 20 over-expression inhibitor.
5. 5. The use according to claim 4, wherein the medicament for treating bladder cancer is a pharmaceutically acceptable carrier comprising a zdhc 20 gene overexpression inhibitor.

Description

Biomarker for diagnosing bladder cancer and application thereof Technical Field The invention relates to the technical field of biological medicines, in particular to a biomarker for diagnosing bladder cancer and application thereof. Background The occurrence and development of bladder cancer is a complex process involving multiple factors. On one hand, the occurrence of the compound is closely related to epidemiological factors such as smoking, occupational exposure and the like, and on the other hand, the compound also relates to multi-level biological regulation and control, including gene mutation, abnormal gene expression, the combined action of multiple mechanisms such as cell behaviors, immune response, tumor microenvironment and the like. Despite recent intensive research, the molecular events that have been revealed at present reflect only a part of the bladder cancer regulation network. Studies have shown that there is a complex and broad cross-regulatory relationship between multiple signal pathways, and common upstream regulatory factors for these pathways have not been fully elucidated. Notably, many genes reported to be associated with bladder cancer, while capable of promoting tumor progression, are often insufficient to drive tumorigenesis alone. Furthermore, there are significant differences in the mutation or expression pattern of these genes between patients, suggesting that they may not be stable and central regulatory factors in the tumorigenesis process. Thus, current early screening and intervention strategies based on individual genes still face certain limitations in clinical popularization. The system identifies and analyzes key molecular events capable of driving bladder cancer to occur, and has important significance for establishing effective early warning indexes and accurate prevention strategies. The zinc finger DHHC palmitoyltransferase family (zdhc) is a class of enzymes capable of catalyzing palmitoylation modification of proteins, and its mechanism of action is to transfer the palmitic acid group in palmitoyl coa to a cysteine residue of a target protein, thereby regulating the localization, stability and function of the protein. Early studies on this family of proteins have focused mainly on the field of metabolic diseases, and then gradually expanded to the direction of researches on nervous system diseases and immune regulation. In recent years, more and more research has begun focusing on the role of the zdhc family in tumorigenic development. Disclosure of Invention In order to solve the defects and shortcomings of the prior art, the invention provides a biomarker for diagnosing bladder cancer and application thereof, and proves that the over-expression of ZDHC 20 can activate a plurality of cancer promotion signal paths, and can induce human bladder epithelial cells to generate malignant transformation without other exogenous stimulation, so that the ZDHC 20 can play a key driving role in the bladder cancer generation process. The invention adopts the technical proposal that the biomarker for diagnosing bladder cancer is enzyme ZDHC 20 which catalyzes protein palmitoylation modification. Application of biomarker ZDHC 20 detection reagent in preparation of reagent for detecting and diagnosing bladder cancer. The biomarker ZDHC 20 is an early diagnosis marker for bladder cancer. Application of ZDHC 20 as target in preparing medicine for treating bladder cancer. Further, the medicament for treating bladder cancer is a ZDHC 20 over-expression inhibitor. Further, the medicament for treating bladder cancer is a pharmaceutically acceptable carrier containing the over-expression inhibition of the ZDHC 20 gene. The invention has the beneficial effects that the invention provides the biomarker for diagnosing the bladder cancer and the application thereof, and the single cell transcriptome data of normal bladder epithelial cells and bladder cancer cells are analyzed, so that the ZDHC 20 is continuously increased in the process of converting the bladder epithelial cells into malignant cells and is remarkably high in expression in human bladder cancer tissues, and functional researches show that the ZDHC 20 over-expression can remarkably activate cancer-promoting signal paths such as PI3K/AKT, wnt/beta-catenin, cell cycle and the like, so that the normal bladder epithelial cells can obtain the malignant growth capacity independent of adherence. The above results indicate that zdhc 20 is an important molecule driving malignant transformation of bladder epithelial cells. The invention discloses a key role of ZDHC 20 in bladder cancer occurrence, which indicates that ZDHC 20 can be used as a bladder cancer diagnosis and treatment target. Drawings FIG. 1-excavation of key molecules driving bladder epithelial cell degeneration. Single cell sequencing data of normal and bladder cancer tissues (20:20) were processed and cells highly expressing the BC oncogene and maintaining the NBU st